FAAH Inhibitor Improves Function of Inflamed Bladders by Modulation of Anandamide and Palmitoylethanolamide

Ana Charrua; Rita Matos; Tim Marczylo; Istvan Nagy; Francisco Cruz

doi:10.24915/aup.34.3-4.14

Authors

Ana Charrua i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal; IBMC – Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal; Departamento de Doenças Renais, Urológicas e Infeciosas, Faculdade de Medicina da Universidade do Porto, Porto, Portugal; Departamento de Biologia Experimental, Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Rita Matos Departamento de Biologia Experimental, Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Tim Marczylo Public Health England, Chilton, UK
Istvan Nagy Department of Surgery & Cancer, Faculty of Medicine, Imperial College of London, London, UK
Francisco Cruz i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal; IBMC – Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal; Departamento de Doenças Renais, Urológicas e Infeciosas, Faculdade de Medicina da Universidade do Porto, Porto, Portugal; Departamento de Urologia, Hospital S. João, Porto, Portugal

DOI:

https://doi.org/10.24915/aup.34.3-4.14

Keywords:

Anti-Inflammatory Agents, Arachidonic Acids, Endocannabinoids, Palmitic Acids, Pain, Urinary Bladder

Abstract

Introduction: We aim to study the effect of fatty acid amide hydrolase (FAAH) blockade on bladder hyperactivity and on fatty acid amides levels during cystitis.

Material and Methods: Cystitis was induced in female Wistar rats using 5 mg/mL lipopolysaccharide (LPS). Control group were intravesical instilled with saline. LPS and control groups received intravenously (caudal vein) during cystometry: URB 937 (URB; FAAH antagonist) in doses of 0.007, 0.07, 0.7 and 7 mg/kg (cumulative, with 10 minutes interval). Using the maximal effective dose of URB (0.7 mg/kg, see below) animals received 10 uM MJ15 (CB1 receptor antagonist) or 0.3 mg SR144528 /kg (SR; CB2 receptor antagonist). At dose of 7 mg/kg, animals receive 1.4 μg SB366791/kg (SB; TRPV1 antagonist). Control and inflamed (without and with 0.7 and 7 mg/kg URB) group were euthanized and the bladder was harvested for the determination of anandamide (AEA) and palmitoylethanolamide (PEA) by mass spectrometry.

Results: Frequency of control was not changed by URB treatment at any dose. LPS increase bladder frequency. 0.007 mg and 0.07 mg URB decrease bladder frequency of LPS-inflamed rats. 0.7 URB reversed LPS-induced bladder hyperactivity. At 7 mg, URB was unable to reverse or reduce LPS-induced bladder hyperactivity. The administration of CB1, CB2 and TRPV1 antagonists did not change the frequency of voiding contractions of naïve animals. CB1 antagonist reversed the effect of 0.7 URB while TRPV1 antagonist reduced the effect of 7 URB. AEA levels increase during inflammation. Treating LPS-inflamed animals with 0.7 mg URB brought AEA levels to control levels. Treating LPS-inflamed animals with 7 mg URB did not change AEA levels, compared to LPS-inflamed animals. PEA levels decrease during inflammation. Treating LPS-inflamed animals with 0.7 mg URB brought AEA levels to control levels. Treating LPS-inflamed animals with 7 mg URB, decreased PEA levels to values similar to the ones observed in LPS- -inflamed animals.

Conclusion: During cystitis, the FAAH inhibitor raises the levels of PEA and reverses the urinary frequency by a CB1 receptor- mediated mechanism. When used in very high doses, the FAAH antagonist raises the levels of AEA and increases the urinary frequency by a TRPV1-dependent mechanism. Therefore, the choice of FAAH inhibitor dosage to be used in the clinics should consider the putative effects over the endocannabinoid levels in the system.

Downloads

Download data is not yet available.

References

1. Charrua A, Cruz CD, Cruz F, Avelino A. Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder overactivity in cystitis. J Urol. 2007;177:1537-41.
2. Pertwee RG, Fernando SR. Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol. 1996;118:2053-8.
3. Dinis P, Charrua A, Avelino A, Yaqoob M, Bevan S, Nagy I, et al. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal
dorsal horn neurons in cystitis. J Neurosci. 2004;24:11253-63.
4. Hermann H, De Petrocellis L, Bisogno T, Schiano Moriello A, Lutz B, Di Marzo V. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci. 2003;60:607-16.
5. Ho WS, Barrett DA, Randall MD. ‘Entourage’ effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol. 2008;155:837-46.
6. Pessina F, Capasso R, Borrelli F, Aveta T, Buono L, Valacchi G, et al. Protective effect of palmitoylethanolamide in a rat model of cystitis. J Urol. 2015;193:1401-8.
7. Sun YX, Tsuboi K, Okamoto Y, Tonai T, Murakami M, Kudo I, Ueda N. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J.
2004;380(Pt 3):749-56.
8. Sugiura T, Kobayashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids. 2002;66:173-92.
9. Taylor BK. N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia. Pain. 2013;154:326-7.
10. Merriam FV, Wang ZY, Hillard CJ, Stuhr KL, Bjorling DE. Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation. BJU Int. 2011;108:1145-9.
11. Strittmatter F, Gandaglia G, Benigni F, Bettiga A, Rigatti P, Montorsi F, et al. Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in
awake rats. Eur Urol. 2012;61:98-106.
12. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc
Natl Acad Sci U S A. 2001;98:9371-6.
13. Maccarrone M, De Petrocellis L, Bari M, Fezza F, Salvati S, Di Marzo V, et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes.
Arch Biochem Biophys. 2001;393:321-8.
14. Holt S, Nilsson J, Omeir R, Tiger G, Fowler CJ. Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. Br J Pharmacol. 2001;133:513-20.
15. Farquhar-Smith WP, Rice AS. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology. 2001;94:507-13; discussion 6A.
16. Fogaca MV, Gomes FV, Moreira FA, Guimaraes FS, Aguiar DC. Effects of glutamate NMDA and TRPV1 receptor antagonists on the biphasic responses to anandamide injected into the dorsolateral periaqueductal grey
of Wistar rats. Psychopharmacology. 2013;226:579-87.
17. Kaczocha M, Glaser ST, Deutsch DG. Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci U S A. 2009;106:6375-80.
18. Fowler CJ. Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J. 2013;280:1895-904.
19. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol. 2003;140:802-8.
20. Maccarrone M, Dainese E, Oddi S. Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci. 2010;35:601-8.
21. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem. 2006;281:36569-78.
22. Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids
but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012;153:1837-46.
23. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces
inflammatory and noninflammatory pain. J Pharmacol Exp Ther. 2011;338:114-24.
24. Li GL, Winter H, Arends R, Jay GW, Le V, Young T, et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol.
2012;73:706-16.